In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Franck Touret; Magali Gilles; Karine Barral; Antoine Nougairede; Etienne Decroly; Xavier de Lamballerie; Bruno Coutard.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-023846

Documentos relacionados

  1. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
  2. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
  3. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial.
  4. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
  5. Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro.
  6. Post-COVID-19 neuropsychiatric manifestations: a suggested therapeutic approach to 'long COVID' with azithromycin.
  7. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
  8. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
  9. Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2.
  10. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.